cepharanthine has been researched along with Alopecia Areata in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Hagiwara, K; Iwabuchi, T; Kiso, A; Ogura, K; Sugano, M; Tamba, K; Tsunekawa, Y | 1 |
| Inui, S; Itami, S | 1 |
| Kishi, T; Miyachi, Y; Morita, K; Nagamachi, M; Nakamura, M | 1 |
3 other study(ies) available for cepharanthine and Alopecia Areata
| Article | Year |
|---|---|
Cepharanthine induces the proliferation of human dermal papilla cells and stimulates vascular endothelial growth factor expression through increased intracellular calcium mobilization and hypoxia-inducible factor activation.
Topics: Alopecia Areata; Anti-Inflammatory Agents, Non-Steroidal; Benzylisoquinolines; Calcium; Cell Line; Cell Proliferation; Hair; Humans; Molecular Structure; Real-Time Polymerase Chain Reaction; Skin; Vascular Endothelial Growth Factor A | 2021 |
Induction of insulin-like growth factor-I by cepharanthine from dermal papilla cells: a novel potential pathway for hair growth stimulation.
Topics: Alopecia Areata; Anti-Inflammatory Agents, Non-Steroidal; Benzylisoquinolines; Cells, Cultured; Drug Evaluation, Preclinical; Hair; Humans; Insulin-Like Growth Factor I; Male; Phytotherapy; Plant Extracts | 2013 |
Seventeen cases of alopecia areata: combination of SADBE topical immunotherapy with other therapies.
Topics: Adjuvants, Immunologic; Administration, Oral; Administration, Topical; Adolescent; Adult; Alkaloids; Alopecia Areata; Benzylisoquinolines; Child; Combined Modality Therapy; Cryotherapy; Cyclobutanes; Female; gamma-Aminobutyric Acid; Humans; Immunotherapy; Male; Middle Aged | 2002 |